Recent Finacing
Recent Raise
TauRx develops tau aggregation inhibitors (LMTX/HMTM) and diagnostics for tauopathies, running global Phase 3 clinical trials for Alzheimer’s disease and frontotemporal dementia from Singapore headquarters with research in Aberdeen.
